By Robert King
Several advocacy groups are pressing Congress to allocate more COVID-19 relief funding for providers, but with a twist to give more money to providers that participate in alternative payment models.
read more
By Amirah Al Idrus
In the early days of COVID-19, the Alliance for Regenerative Medicine was unsure how the pandemic and its accompanying economic downturn would affect the cell and gene therapy space. Now, the numbers are in—and they’re better than ever. In the first half of 2020, the sector raised $10.7 billion, more than the total it raised in 2019.
read more
By Angus Liu
The Trump administration’s surprising $765 million deal to help former photography giant Kodak to start making drug ingredients has yet to be finalized, and it’s already attracted plenty of controversy. First, insider trading allegations from the U.S. Senate—and now, an investigation by House Democrats.
read more
By Heather Landi
The COVID-19 pandemic offers an opportunity for a practice and policy "reset" to help permanently reduce administrative headaches for physicians, according to two healthcare leaders. Here is why two doctors believe there are important policy lessons to be learned from the current pandemic.
read more
By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner
Gilead's antiviral remdesivir and Merck KGaA's interferon-based med Rebif are teaming up against coronavirus in a new NIH trial. The German drugmaker's CFO has some thoughts about vaccine timing. A radiology collab aims to use AI and imaging to quickly diagnose cases. And researchers in South Korea confirmed what experts already believed: Asymptomatic people do spread COVID-19.
read more
By Conor Hale
The NIH is turning to AI and medical imaging to not only detect cases of COVID-19 earlier, but to help personalize treatments for the spreading disease.
read more
By Paige Minemyer
Employers are making adjustments to their health benefits in the wake of COVID-19, but workers may not take the time to consider these new options, a survey from Fidelity shows.
read more
By Eric Sagonowsky
Shortly after issuing four drug pricing executive orders—including one that generated significant pushback from the pharmaceutical industry—President Donald Trump is set to sign another centered on U.S. production for drugs and medical supplies, according to reports. Pharma's not likely to be any happier this time.
read more
By Fraiser Kansteiner
Catalent has made waves of late with a series of high-profile coronavirus vaccine deals. Now, the New Jersey-based CDMO is plotting an upgrade to its plant in Buenos Aires, where it aims to churn out high-potency treatments for diseases like cancer, to the tune of 10 million additional doses per year.
read more
